ATX-101 for reduction of submental fat.

Article Details

Citation

Wollina U, Goldman A

ATX-101 for reduction of submental fat.

Expert Opin Pharmacother. 2015 Apr;16(5):755-62. doi: 10.1517/14656566.2015.1019465. Epub 2015 Feb 27.

PubMed ID
25724831 [ View in PubMed
]
Abstract

INTRODUCTION: Facial esthetics are important for self-esteem. Undesired submental fat (SMF) deposits lead to an unappealing submental profile associated with aging and overweight. Compound ATX-101 is a proprietary formulation of purified synthetic deoxycholic acid for pharmacological submental contouring. Review areas covered: This reviews covers anatomy of SMF, biochemistry of deoxycholic acid related to adipose tissue and tissue response to injection of ATX-101. Data from clinical trials were analyzed for efficacy and safety. METHODOLOGY: Published studies using PubMed((c)) database 2000 - 2014 have been analyzed. The terms 'deoxycholate', 'deoxycholic acid', 'ATX-101' and 'injection lipolysis' were used. RESULTS: Deoxycholic acid causes adipocyte breakdown and an inflammatory tissue reaction leading to fat cell reduction and limited fibrosis. Four large clinical Phase III trials demonstrated efficacy of ATX-101 in reduction of SMF measured by validated scales and objective measurements. Patients reported improved psychological features and feeling. Adverse effects were mild and temporary. EXPERT OPINION: Adipocytolysis of SMF by ATX-101 is an important step forward to the development of approved drugs for reduction of localized fat pads. This could become a growing market.

DrugBank Data that Cites this Article

Drugs